FDA-Inspected Site

Exela Pharma Sciences, LLC.

17 FDA inspections are on record for Exela Pharma Sciences, LLC. in Lenoir, United States.

483· Form 483 issued

Lenoir, United States · Last updated July 9, 2026

Overview

  • 17 FDA inspections are on record.
  • 8 inspections produced a Form 483.
  • The most recent recorded inspection date is 2024-11-15.

At a glance

Inspections

17

Form 483s

8

EIRs

2

Last outcome

Form 483

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
4 Nov 2024 – 15 Nov 2024Human DrugsWLOn file
6 Dec 2021 – 10 Dec 2021Human DrugsClean
15 Oct 2019 – 22 Oct 2019Human DrugsClean
14 Oct 2019 – 22 Oct 2019Human DrugsClean
10 Jun 2019 – 18 Jul 2019Human DrugsWLView 483 →
18 Mar 2019 – 29 Mar 2019Human Drugs483View 483 →
12 Dec 2018 – 19 Dec 2018Human DrugsClean
7 Sep 2018 – 11 Sep 2018Human DrugsClean
23 Oct 2017 – 27 Oct 2017Human Drugs483On file
19 Sep 2017 – 28 Sep 2017Human Drugs483View 483 →
6 Jun 2016 – 8 Jun 2016Human DrugsClean
17 Nov 2014 – 21 Nov 2014Human Drugs483On file

Observations on record

Form 483 observations cited at this site, most recent first.

18 Jul 2019
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Samantha J Bradley

18 Jul 2019
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Samantha J Bradley

18 Jul 2019
21 CFR 211.188

Prepared for each batch, include complete information

Cited by Samantha J Bradley

18 Jul 2019
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Samantha J Bradley

18 Jul 2019
21 CFR 211.42(c)(10)(iv)

Environmental Monitoring System

Cited by Samantha J Bradley

Investigators

FDA investigators tied to this site in the record.

Penny H Mccarver2 insp.
Megan T Ziegler1 insp.
Jawaid Hamid1 insp.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations4x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations3x
21 CFR 211.113(b)Cited across public-safe Form 483 observations2x
21 CFR 211.160(b)Cited across public-safe Form 483 observations2x
21 CFR 211.188Cited across public-safe Form 483 observations2x
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.25(a)Cited across public-safe Form 483 observations2x
21 CFR 211.67(a)Cited across public-safe Form 483 observations2x
21 CFR 211.68(a)Cited across public-safe Form 483 observations2x
21 CFR 211.100(b)Cited across public-safe Form 483 observations1x
21 CFR 211.110(b)Cited across public-safe Form 483 observations1x
21 CFR 211.122(a)Cited across public-safe Form 483 observations1x
21 CFR 211.125(a)Cited across public-safe Form 483 observations1x
21 CFR 211.130(d)Cited across public-safe Form 483 observations1x
21 CFR 211.134(c)Cited across public-safe Form 483 observations1x
21 CFR 211.150Cited across public-safe Form 483 observations1x
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(b)Cited across public-safe Form 483 observations1x
21 CFR 211.180(e)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.182Cited across public-safe Form 483 observations1x
21 CFR 211.186(b)(8)Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x
21 CFR 211.42(b)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(v)Cited across public-safe Form 483 observations1x
21 CFR 211.58Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x
21 CFR 211.80(a)Cited across public-safe Form 483 observations1x
21 CFR 211.80(b)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.94(c)Cited across public-safe Form 483 observations1x
21 CFR 314.80(b)Cited across public-safe Form 483 observations1x
FDCA 503B(a)(10)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind Exela Pharma Sciences, LLC.'s 8 Form 483s

Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat